Synergy CHC Corp. (SNYR) Peer Comparison

$0.11

$0.00 (-1.79%)

As on 03-Sep-2026 16:21EDT

Market cap

$2 Mln

Revenue (TTM)

$28 Mln

P/E Ratio

--

P/B Ratio

0.9

Div. Yield

0 %

Edit

	Synergy CHC Corp. (SNYR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	2	12,753	10,906	9,948	9,762
Revenue ($ Mln)	28	1,505	613	785	2,589
Net Profit ($ Mln)	-15.79	160.59	-188.05	41.54	222.40
Net Margin (%)	-56.98	10.67	-30.68	5.29	8.59
RoE (%)	--	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.81	44.47
Price-To-Book	0.91	8.41	16.38	4.86	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Synergy CHC Corp. (SNYR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	27.70	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	9.66	483.98	127.96	384.30	1,245.50
Gross Profit	20.30	942.44	393.22	347.62	1,343.60
Operating Expenses	26.20	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-4.31	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-15.67	203.83	-192.83	52.15	350.40
Provision for Tax	0.17	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-15.79	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Synergy CHC Corp. (SNYR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	-25.41	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	25.02	210.18	135.71	705.49	2,116.80
Current Liabilities	6.85	233.78	102.33	132.66	961.30
Total Liabilities	10.16	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Synergy CHC Corp. (SNYR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	0.12	630.60	404.74	1,749.63	7,231.50
Current Assets	6.34	1,344.12	515.78	1,200.55	3,020.50
Total Assets	10.16	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	27.75	212.71	102.84	690.94	1,203.70
Net Current Assets	-0.50	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Synergy CHC Corp. (SNYR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	-2.59	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	--	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	4.65	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Synergy CHC Corp. (SNYR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-169.40	11.76	-22.53	1.79	8.98
ROE (%)	62.08	10.86	-28.10	1.97	3.04
ROA (%)	-85.26	7.95	-18.00	1.36	2.02
EBIT Margin (%)	16.17	13.63	-30.58	9.87	-5.99
Net Margin (%)	-56.98	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Synergy CHC Corp. (SNYR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	-17.53	17.55	41.55	16.49	1.37
EBIT Growth (%)	-30.83	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	-752.14	8.72	-102.66	400.42	-30.32
EPS Growth (%)	-543.18	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	-23.27	17.33	-12.65	2.16	2.19

Valuation Ratios

	Synergy CHC Corp. (SNYR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-1.70	68.93	-34.59	189.42	--
Price / Book Value	-0.91	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-7.33	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Synergy CHC Corp. (SNYR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	-0.98	0.00	0.00	0.26	0.11
Short term debt to equity ratio	-0.11	0.01	0.00	0.01	0.06
Current Ratio	0.93	5.75	5.04	9.05	3.14
Quick Ratio	0.43	3.86	4.46	7.64	2.33
Interest Coverage	-1.29	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Synergy CHC Corp. (SNYR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	4.58	12.65	22.67	20.09	17.06
Asset Turnover	1.50	0.74	0.59	0.26	0.24
Receivable days	89.56	46.54	60.95	72.41	65.39
Inventory Days	98.83	331.92	193.84	146.53	221.09
Payable days	--	26.16	60.19	29.05	37.02
Cash Conversion Cycle	--	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly